Dendritic Cell Vaccine Therapy for Breast Cancer Micro-Metastases.
Abstract
This project is studying the development of dendritic cell vaccines for immune therapy of breast cancer. We have developed techniques for isolation and immunogen loading of murine splenic dendritic cells which induced humoral and cellular immunity in a model system (BSA). Translation to a tumor antigen (CEA) produced weak immune responses and antitumor effects. This system requires large amounts of immunogen to be effective. An alternate approach of developing gene transfer techniques to induce immunogen expression in dendritic cells is ongoing. We have developed a vector system using replication defective adenoviruses which is able to transfect dendritic cells as demonstrated with luciferase (reporter gene). We have constructed a CEA vector (Ad-CEA) which induces CEA expression in cells (in vitro); it induced antibody to CEA following IV and IP injection but not antitumor effects (TH-2 response). Generation of Ad-CEA dendritic cell vaccines are ongoing and already show evidence of CEA immune responses. We will examine these Ad-CEA dendritic cell vaccines as therapy in metastatic breast cancer models and examine strategies to switch the Ad-CEA (alone) system to a more effective immune response (TH-1 response). We are constructing adenovirus-Erb-2 constructs as a second breast cancer relevant system.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 06, 1995
- Accession Number
- ADA303675
Entities
People
- Albert F. Lobuglio
Organizations
- University of Alabama